CollPlant Biotechnologies Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.47next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly GAAP Revenue Quarterly73K
Cash and Cash Equivalents Quarterly4.3M
Annual GAAP Revenue Annually2.4M
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Monitor closing bid price and consider options (such as a reverse share split) to regain compliance by the September 21, 2026 deadline.
- Strategic Alternatives ReviewTrigger: Initiation of formal review processAction: Evaluate potential collaborations, acquisitions, business combinations, or other strategic transactions to maximize shareholder value.
- Preclinical and Clinical Progress of Photocurable Dermal FillerTrigger: Transition from final preclinical stage to clinical trialsAction: Initiate clinical studies within the next two years and secure strategic partners for development and commercialization.
Research as of 20 Jun 2026